ClinicalTrials.gg

Program

encequidar

Also written as “HM30181AK tablet + Irinotecan tablets”, “Oral Paclitaxel in combination with Encequidar tablet” and “Encequidar tablet”.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Furthest: phase 3, since Aug 6, 20096 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical40 open or runningphase 1since Aug 6, 2009Aug 6, 2009none ahead
Health Hope Pharma22 open or runningphase 3since Feb 14, 2025Feb 14, 2025Dec 2026phase 1 · NCT07580833

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2009First study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT00954304 · 30 enrolled · Korea, Republic of
  2. Sep 16, 20092 phase 1 studies in Advanced Solid MalignanciesHanmi Pharmaceutical · NCT00979563, NCT00986843
  3. Dec 5, 2011Phase 1 study in Advanced Solid TumorsHanmi Pharmaceutical · NCT01491204 · 25 enrolled
  4. Feb 14, 2025Health Hope Pharma's first study: phase 3 study in Breast NeoplasmsNew to Health Hope PharmaHealth Hope Pharma · NCT06835400 · 340 planned
  5. Mar 24, 2026Phase 1 study in Breast NeoplasmsHealth Hope Pharma · NCT07580833 · 46 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Breast NeoplasmsHealth Hope Pharma · NCT07580833
  2. Apr 2028Primary completion: phase 3 study in Breast NeoplasmsHealth Hope Pharma · NCT06835400

TargetBeta

ABCB1 →read by rule
“P-glycoprotein 1 inhibitor”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07580833Breast Neoplasms1Not yet recruitingHealth Hope PharmaDec 202646
NCT06835400Breast Neoplasms3Not yet recruitingHealth Hope PharmaApr 2028340
NCT01491204Advanced Solid Tumors1CompletedHanmi PharmaceuticalOct 200825
NCT00986843Advanced Solid Malignancies · Korea, Republic of1CompletedHanmi PharmaceuticalFeb 201014
NCT00979563Advanced Solid Malignancies · Korea, Republic of1CompletedHanmi PharmaceuticalMar 201015
NCT00954304Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalAug 200930

How it is read

Names in the registry

  • “HM30181AK tablet + Irinotecan tablets”, 2 entries
  • “Oral Paclitaxel in combination with Encequidar tablet”, 1 entry
  • “Encequidar tablet”, 1 entry
  • “Paclitaxel+HM30181”, 1 entry
  • “HM30181AK 1mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.